Hepatitis B is the most important cause of cirrhosis in developing countries.[@ref1] Complications of this infection are chronicity, hepatocellular carcinoma and chronic active hepatitis.[@ref2] Blood and other secretions of patients have virus and are infective.[@ref3][@ref4] The most important sources of infections are blood, saliva and semen.[@ref5] Hospital equipments such as mechanical ventilators, endoscopes, and hemodialysis machines can transmit this viral infection.[@ref6][@ref7] Hemodialysis patients are susceptible to infection due to repeated contact with dialysis machines and blood products.[@ref2][@ref8][@ref9] Intramuscular (deltoid) vaccination in months 0, 1 and 6 is the standard method and after immunization, HBS antibody titer should be greater than 10 mu/ml.[@ref10] Approximately 90-95% of healthy people and 45-50% of dialysis patients properly respond to vaccination.[@ref11][@ref12] To increase efficacy of vaccination in dialysis patients, different methods of vaccination such as high dose of intramuscular, subdermal, intradermal and adding adjuvant as erythropoietin or interleukin have been administrated.[@ref13][@ref14]

Methods {#sec1-1}
=======

In a cross-sectional study in 78 hemodialysis patients of Hajar Hospital of Shahrekord University of Medical Sciences, 24 patients that did not respond to conventional method of vaccination in this center (double dose in 0, 1 and 6 months) and had antibody titer less than 10 mu/ml, were enrolled to intramuscular or intradermal group, randomly. In intradermal (ID) group, 10 μg (0.5 ml) recombinant vaccine was prescribed every 2 weeks to 6 months and in intramuscular (IM) group, 40 μg (2 ml) at 0, 1, 2 and 6 months were prescribed and the antibody titers were checked after 1 and 3 months of the end of vaccination. Inclusion criteria were age greater than 18 years and having at least 3 months dialysis. Exclusion criteria were as follows: 1- incompliance during study, 2- vaccination with methods other than conventional 3 doses, and 3- injection of booster dose. After the end of study, data were entered to SPSS software (Statistical Package for the Social Sciences, version 13.0 SPSS Inc, Chicago, IL) and Mann-Whitney and Spearman tests were used for statistical analysis. All data and information were confidential and for vaccination, an informed consent was taken from the patients. This study was approved in ethic committee of Shahrekord University of Medical Sciences.

Results {#sec1-2}
=======

In 24 patients studied (14 males and 10 females), mean age was 55.1 ± 18.6 years. Mean age of the patients in the two groups had no significant difference (p = 0.85). Cause of renal failure in 10 patients was diabetic nephropathy, in 8 patients was hypertensive nephrosclerosis, in 2 patients was chronic glomerulonephritis and in 4 patients was unknown.

Mean body mass index (BMI) was 23.3 ± 4.2 and there was no significant difference between the two groups (p = 0.39). Mean HBsAg specific antibody titer in patients was 4.4 ± 3.1 mu/ml at the beginning of study (minimum of 1.1 mu/ml and maximum of 9.2 mu/ml) and after 1 month and 3 months, mean HBsAg antibody titer was 190.4 ± 59 and 223.3 ± 83.9, respectively (p \< 0.001). After one month, in intradermal and intramuscular groups, mean HBsAg antibody was 198.8 ± 75.6 mu/ml and 181.2 ± 61.8 mu/ml, respectively (p = 0.5) and after 3 months, was 230 ± 76 mu/ml and 216.2 ± 94.3 mu/ml, respectively (p = 0.83).

Mean duration of dialysis in patients was 48.6 ± 46.6 months (minimum of 7 and maximum of 217).

Three patients had hepatitis C. Fifty patients were 50 years or more than 50 years old and 10 patients had less than 50 years. There was no correlation between age and antibody titer ([Table 1](#T1){ref-type="table"}).
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Duration of dialysis in 11 patients was less than 36 months and in 13 patients was equal or more than 36 months. Mean HBsAg antibody titer after one month in the above two groups was 221.5 ± 37.7 mu/ml and 158.6 ± 47.8 mu/ml, respectively (p = 0.01) and after 3 months was 251.4 ± 61.2 mu/ml and 193.9 ± 90.7 mu/ml, respectively (p = 0.17). Frequency of dialysis was 2 times per week in 5 patients and 3 times per week in 19 patients. There was no significant correlation between frequency of dialysis and HBsAg antibody titer ([Table 2](#T2){ref-type="table"}).
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Mean antibody titer after 1 and 3 months of the end of vaccination based on vaccination method, age and gender
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Discussion {#sec1-3}
==========

The aim of our study was comparison of two methods of hepatitis B vaccination. Different methods of vaccination have been offered to increase the rate of seroconversion in hemodialysis patients. In Morais et al study, patients with antibody titer less than 10 mu/ml were recived low dose of intradermal HB vaccinne and in 82% of patients, antibody titer were greter than 10 mu/ml and age, duration of dialysis, smoking, and BMI of patients had no correlation with antibody titer.[@ref15] In 35 dialysis patients, intradermal vaccination led to seroconvertion in 96% of patients in Mat et al study.[@ref16] In Sorkhi et al study, low dose intradermal and subcutaneous vaccination caused less seroconversion versus intramuscular method.[@ref17] In Fabrizi et al study, incresed dose of Engrix from 20 to 40 μg, increased the seroconversion rate.[@ref18] Chou showed that low dose hepatitis B vaccination incresed HBS antibody titer in the first 6 months but decresed it during the next 2 years.[@ref19] In Sombonsilip et al study, there was no difference between ID or IM vaccination and two methods were equally effective in seroconversion.[@ref20] Beleed showed that boster dose of vaccine is effective in efficacy of vaccination and is essential each year.[@ref21] In Choy et al study, in 24 dialysis patients that did not respond to IM method, ID vaccination with IM booster dose was effective.[@ref22] In Fabrezi et al study, age of patients was not correlated with seroconversion rate[@ref23] and in our study also similar result was achieved. In our study, BMI and dialysis frequency per week had no correlation with antibody titer; these results are comparable with Morais et al study results.[@ref15] Three patients had hepatitis C and in these patients, antibody titer was not different with that in other patients but in Bock et al study, antibody titer in these patients were lower than that in other patients.[@ref24] Discrepancy between these results may be due to difference between number of patients in two studies. In our study, antibody titer was high (\> 50 ul/ml) in two groups after 1 and 3 months of vaccination and no significant difference was observed between the 2 groups. Results of this study correlated with Sorkhi et al[@ref17] and Choy et al[@ref22] studies and different with Chau et al[@ref19] study. In the review study written by Edey et al, results of different methods were illustrated; in some of them, intradermal method had higher rate of antibody titer production.[@ref25] In patients with dialysis duration greater than 36 months, there was lower antibody titer after 1 month (may be due to suppression of immune system by renal failure and dialysis) but this effect was transient and after 3 months of vaccination, this difference disappeared. Probably, dialysis duration has an inhibitory effect on rising HBS antibody titer, transiently. Results of this study showed that two methods of vaccination (high dose IM and low dose SC) are effective and the selection of vaccination method could be based on health policy.
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